Reading Time: 4 minutes This is blog number 17 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Drug discovery can be…
Reading Time: 4 minutes Recently published results from the open-label Lighthouse trial investigating safety of the drug Triumeq in people with MND revealed the treatment was safe and ready to progress to a larger Phase 3 clinical trial. The trial was held in Australia and recruited 40 people with MND who all received the active drug; this was because…
Reading Time: 3 minutes There is recent evidence to suggest that Human Endogenous Retroviruses (HERVs) may be involved in amyotrophic lateral sclerosis (ALS). HERV-K has been directly linked to motor neurone damage and has been found in the brain tissue of patients with ALS. The MND Association recently awarded a small grant to fund part of the ‘Lighthouse Project’…
Reading Time: 2 minutes New research from scientists at the American National Institute of Neurological Disorders and Stroke in Bethesda suggest that they might. In a research paper published in Science Translational Medicine yesterday, Li, Nath and colleagues proposed that sporadic MND may be linked to an endogenous retrovirus called ‘HERV-K’. So they conducted a series of experiments to…
